Want to see KYNB full AI Analyst Report?
Top Page
Kyntra Bio
(NASDAQ:KYNB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.00
▼(-37.11% Downside)
Action:Reiterated
Date:10/07/26
The score is held down primarily by weak financial performance (declining revenue, ongoing cash burn, negative equity) and bearish technicals (price below key moving averages with negative MACD). Offsetting factors include a somewhat constructive earnings call with near-term clinical catalysts and a stated cash runway into 2028, while valuation looks optically cheap but is undermined by low earnings quality and poor cash conversion. Corporate events add additional risk due to the Nasdaq delisting overhang.
Positive Factors
Clinical Pipeline
FG-3246 has advanced into a defined Phase II program with a sizable enrollment target and a scheduled interim readout. This creates a tangible development path and near-term evidence point, while the companion imaging strategy may support patient selection and differentiation.
Negative Factors
Weak Operating Performance
Contracting revenue, deeply negative operating profitability, and continued cash consumption indicate that the business is not yet self-funding. The mismatch between reported net income and operating cash flow also reduces confidence in earnings quality and may constrain sustained investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Pipeline
FG-3246 has advanced into a defined Phase II program with a sizable enrollment target and a scheduled interim readout. This creates a tangible development path and near-term evidence point, while the companion imaging strategy may support patient selection and differentiation.
Read all positive factors
Kyntra Bio Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks revenue into streams such as product sales, licensing, collaboration income, services, and grants so you can see what actually pays the bills. Highlights whether cash flow is driven by repeatable sales or by one‑time milestone and partnership payments, which affects predictability and near‑term funding needs.
Breaks revenue into streams such as product sales, licensing, collaboration income, services, and grants so you can see what actually pays the bills. Highlights whether cash flow is driven by repeatable sales or by one‑time milestone and partnership payments, which affects predictability and near‑term funding needs.
Data provided by:
The Fly
The FlyKyntra Bio (KYNB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.38M
Dividend YieldN/A
Average Volume (3M)26.54K
Price to Earnings (P/E)<0.1
Beta (1Y)0.74
Revenue Growth-91.38%
EPS GrowthN/A
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,049,124
10 Day Avg. Volume21,148
30 Day Avg. Volume26,542
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap-1.81
Enterprise Value/Revenue-8.39
Enterprise Value/Gross Profit-46.25
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$38.50Price Target Upside384.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-9.65
Revenue Forecast (FY)$6.70M
Kyntra Bio Business Overview & Revenue Model
Company Description
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves...
Kyntra Bio Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.Positive Updates
Promising FG-3246 Early Clinical Activity
Phase I monotherapy: median rPFS 8.7 months, PSA50 response 36%, ORR 20% (in 25 RECIST-evaluable patients) with a meaningful median duration of response of 7.5 months; investigator-initiated study (FG-3246 + enzalutamide) showed median rPFS of 7.0 months overall and 10.1 months in patients with only one prior ARPI (PSA50 40%).
Negative Updates
Revenue Decline Year‑over‑Year
Total revenue was -$1.5M in Q2 2026 versus $1.3M in Q2 2025 (a decline of $2.8M), reflecting an adverse swing in reported revenue versus the prior year period.
Read all updates
Q2-2026 Updates
Positive
Negative
Promising FG-3246 Early Clinical Activity
Phase I monotherapy: median rPFS 8.7 months, PSA50 response 36%, ORR 20% (in 25 RECIST-evaluable patients) with a meaningful median duration of response of 7.5 months; investigator-initiated study (FG-3246 + enzalutamide) showed median rPFS of 7.0 months overall and 10.1 months in patients with only one prior ARPI (PSA50 40%).
Read all positive updates
Company Guidance
The company reiterated specific near-term clinical and financial guidance: as of June 30, 2026 Kyntra reported $95.7M in cash/equivalents/investments/accounts receivable and expects a cash runway into 2028; Q2 2026 revenue was -$1.5M (vs $1.3M prior), operating expenses $16.1M (vs $13.4M), R&D $6.8M (vs $5.9M), SG&A $9.3M (vs $7.1M), and net income from continuing operations was $12.0M or $2.96/share (vs a $13.7M loss, $3.38/share a year ago). Clinical milestones: FG‑3246/FG‑3180 phase II is enrolling 75 post‑ARPI pre‑chemo mCRPC patients across three dose levels (1.8/2.4/2.7 mg/kg) with G‑CSF prophylaxis at 23 live U.S. sites, an interim analysis of 36 patients on track for Q4 2026 (PSA50, ORR, safety, PK, exposure‑response; futility by composite PSA50+ORR), and mature rPFS data expected through 2027 (goal: improve on the phase I median rPFS of 8.7 months and target ≥10 months; phase I: PSA50 36%, ORR 20% of 25 RECIST‑evaluable, DOR 7.5 months at 2.7 mg/kg; IST combo: median rPFS 7.0 months overall and 10.1 months in patients with one prior ARPI; higher FG‑3180 SUV trended with greater PSA50). For roxadustat, the phase III protocol is finalized with a primary endpoint of 8‑week transfusion independence over the first 24 weeks (key secondaries: 12/16/24‑week TI over 48 weeks), a goal to initiate the registrational trial in Q4 2026, dosing to start at 2.5 mg/kg with titration up to 3.5 mg/kg in staged intervals (dose changes possible every ~6 weeks), MATTERHORN post‑hoc high‑transfusion‑burden results showed 36% vs 7% achieving ≥8‑week TI (nominal p=0.041), the program has Orphan Drug status, will enroll RS+ and RS‑ patients, and Kyntra is weighing internal development (would owe AZ a mid‑single‑digit royalty) versus partnering (AZ would receive 35% of economics to Kyntra).Kyntra Bio Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.62M | 6.44M | 29.62M | 46.80M | 140.73M | 235.31M |
| Gross Profit | 838.00K | 5.88M | 14.06M | 42.84M | 120.45M | -213.88M |
| EBITDA | -94.00M | -57.55M | -142.43M | -305.20M | -282.82M | -333.72M |
| Net Income | 183.19M | 183.45M | -47.58M | -284.23M | -293.65M | -290.02M |
Balance Sheet | ||||||
| Total Assets | 101.08M | 119.59M | 214.53M | 423.53M | 610.09M | 773.82M |
| Cash, Cash Equivalents and Short-Term Investments | 91.32M | 88.98M | 50.48M | 235.59M | 422.01M | 405.19M |
| Total Debt | 0.00 | 0.00 | 73.09M | 170.46M | 89.89M | 99.72M |
| Total Liabilities | 109.22M | 115.12M | 398.16M | 585.73M | 611.57M | 544.71M |
| Stockholders Equity | -30.14M | -30.04M | -225.60M | -204.17M | -21.45M | 209.15M |
Cash Flow | ||||||
| Free Cash Flow | -38.06M | -4.81M | -138.26M | -317.54M | -184.67M | -112.42M |
| Operating Cash Flow | -38.05M | -4.77M | -138.00M | -315.02M | -145.93M | -82.23M |
| Investing Cash Flow | 56.14M | 35.42M | 125.99M | 153.66M | 89.12M | -426.97M |
| Financing Cash Flow | -85.94M | -86.03M | -255.00K | 122.75M | 46.78M | -563.00K |
Kyntra Bio Technical Analysis
Negative
7.95
Price Trends
7.02
Negative
7.04
Negative
7.26
Negative
Market Momentum
-0.55
Positive
28.92
Positive
27.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYNB, the sentiment is Negative. The current price of 7.95 is above the 20-day moving average (MA) of 6.04, above the 50-day MA of 7.02, and above the 200-day MA of 7.26, indicating a bearish trend. The MACD of -0.55 indicates Positive momentum. The RSI at 28.92 is Positive, neither overbought nor oversold. The STOCH value of 27.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KYNB.
Kyntra Bio Risk Analysis
Kyntra Bio disclosed 56 risk factors in its most recent earnings report. Kyntra Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kyntra Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $56.19M | -5.66 | -50.77% | ― | 327.25% | 85.65% | |
49 Neutral | $41.65M | -1.57 | -35.78% | ― | ― | -43.60% | |
45 Neutral | $21.38M | 0.09 | -605.53% | ― | -91.38% | ― | |
45 Neutral | $95.57M | -0.66 | -49.02% | ― | ― | 34.92% | |
40 Underperform | $6.77M | -0.12 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
KYNB
Kyntra Bio
5.21
-5.50
-51.35%
GRCE
Grace Therapeutics
1.97
-1.18
-37.46%
OKUR
OnKure Therapeutics
2.30
-0.68
-22.82%
SNTI
Senti Biosciences
0.22
-1.78
-89.15%
XLO
Xilio Therapeutics
8.43
-2.39
-22.11%
Kyntra Bio Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Kyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision
Negative
Oct 6, 2026
On September 30, 2026, Kyntra Bio said it received a determination from Nasdaq staff to delist its common stock after the company failed to demonstrate compliance with Nasdaq Listing Rule 5450(b) by a September 29 deadline. Kyntra Bio has requeste...
Business Operations and StrategyExecutive/Board Changes
Kyntra Bio appoints new independent director, updates governance
Positive
Oct 1, 2026
Kyntra Bio announced leadership changes and governance updates around the end of the third quarter of 2026, underscoring its ongoing efforts to align board expertise with its strategic focus in oncology and rare disease. Effective October 1, 2026,...
Business Operations and StrategyLegal ProceedingsPrivate Placements and Financing
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet
Positive
Aug 31, 2026
On August 31, 2026, Kyntra Bio amended and restated its revenue interest financing agreement with NQ Project Phoebus, cutting the maximum aggregate payments from $125 million to $65 million and eliminating future true-up payments. In return, the c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.